Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly/BI's Basaglar: A Rosier Outlook For US Biosimilars?

Executive Summary

Sales of the insulin glargine product in its first full year on the market were strong at $432.1m, but Lilly said it is offering steep rebates in exchange for market access and it's not clear that the growth is sustainable if more copies enter the market.

Advertisement

Related Content

How Is Pharma Spending Tax Savings? Not On Drug Pricing, Sen. Booker Says
Lilly's Basaglar, Crestor Generics Helped Hold Down Drug Spending Growth In 2017
Rebate Pass-Through Would Lower, Not Raise, Medicare Spending – PhRMA
Sanofi's Admelog, a Humalog Follow-On, Approved In US As 'Black Hole' For Insulins Looms
Payers Like Biosimilars, But Rebates Remain The Bottom Line (For Now)
And Then There Were Three: Lilly's Verzenio Approved For Breast Cancer
Merck's Lantus Copy Lusduna Poised For US Market Pending Litigation
UnitedHealthcare Prefers Basaglar Biosimilar At Lantus' Expense
FDA Biologic Transition Plan Creates 'Dead Zone' For Applications, Sponsors Fear
Sanofi Settlement With Lilly Paves The Way For Biosimilar Lantus

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100303

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel